On June 13th, Alisha Alaimo, the North American head of Biogen, stated at the Goldman Sachs Global Healthcare Conference that Biogen's Alzheimer's drug Leqembi will perform well in the market, whether or not there are competitors. Leqembi was developed jointly by Biogen and its Japanese partner Eisai, and received approval from the US Food and Drug Administration in July last year. The company believes that Eli Lilly and Co's experimental Alzheimer's therapy drug donanemab is a potential competitor. She said that competition or another choice is always a good thing, but more importantly, with Eli Lilly's participation, the market will develop faster. On Monday of this week, the FDA's external advisory group unanimously supported the use of donanemab to treat early Alzheimer's disease, clearing the way for regulatory agencies to make final decisions on the therapy.